Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784926 | 1.00 | CASP3 (0.50) | CASP3KMT2AEPHX2TLR2MDM4 | |
| SCHEMBL1784930 | 1.00 | CASP3 (0.50) | CASP3KMT2AEPHX2TLR2MDM4 | |
| SCHEMBL27577299 | 0.94 | KMT2A (0.53) | CASP3KMT2AEPHX2TLR2MDM4 | |
| SCHEMBL13652764 | 0.93 | TLR2 (0.49) | CASP3KMT2AEPHX2TLR2 | |
| SCHEMBL17193160 | 0.91 | KMT2A (0.51) | CASP3KMT2AEPHX2TLR2MDM4 | |
| SCHEMBL31520508 | 0.90 | KMT2A (0.52) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL28372102 | 0.90 | KMT2A (0.52) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL1828815 | 0.90 | KMT2A (0.52) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL31520522 | 0.90 | KMT2A (0.52) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL29400883 | 0.90 | KMT2A (0.57) | CASP3KMT2AEPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CASP3 282/4885KMT2A 3449/4885EPHX2 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.